ONESOURCEBSEONESOURCE SPECL PHARMA LHighPositive
Announced Fri, 24 Jul · 21:11 IST

OneSource Q1FY27 revenue up 37% YoY, EBITDA up 39%, FY28 guidance reaffirmed

Revenue Growth 20pctEbitda Margin ExpansionPat Growth 25pctExceptional ItemResults View source PDF

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
1-day move
₹1649.00
prior close
₹1695.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.6-3.0-2.9-1.4
Up moveDown movePending
AI summary

Q1FY27 revenue at ₹4,490m, up 37% YoY and 5% QoQ, driven by semaglutide launch and new contracts. EBITDA rose 39% YoY to ₹1,233m with margins expanding to 27.5% (up 600bps QoQ) on operating leverage. Adjusted PAT jumped 72% YoY to ₹637m, EPS ₹5.6. Adjusted figures exclude ₹43m exceptional items and ₹344m scheme amortisation. Management reaffirmed FY28 outlook of $400m organic revenue and 40% steady-state EBITDA margin.

Likely market impact

Strong broad-based growth and margin expansion lift earnings outlook; reaffirmed FY28 guidance signals management confidence.